Renoprotective Effects of a Selective Estrogen Receptor Modulator, Raloxifene, in an Animal Model of Diabetic Nephropathy | Zendy

Alexis Dixon | Zendy; Corinne C. Wells | Zendy; Sandhya Singh | Zendy; Regina Babayan | Zendy; Christine Maric | Zendy

Open Access

Renoprotective Effects of a Selective Estrogen Receptor Modulator, Raloxifene, in an Animal Model of Diabetic Nephropathy

Author(s) -

Alexis Dixon,

Corinne C. Wells,

Sandhya Singh,

Regina Babayan,

Christine Maric

Publication year - 2007

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000099837

Subject(s) - medicine , endocrinology , diabetic nephropathy , streptozotocin , selective estrogen receptor modulator , glomerulosclerosis , raloxifene , estrogen receptor , estrogen , nephropathy , excretion , diabetes mellitus , proteinuria , kidney , cancer , breast cancer

Our previous studies have shown that supplementation with 17beta-estradiol (E2) from the onset of diabetes attenuates diabetic nephropathy. However, E2 is accompanied by feminizing effects as well as adverse side effects on other organs. The current study examined the renoprotective effects of a selective estrogen receptor modulator, raloxifene (RAL), in an experimental model of diabetic nephropathy. RAL activates estrogen receptors and estrogen-receptor-mediated cellular events without the side effects of E2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research